Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1252W HIGH $12.29
Volume
3.40 M
Value Traded
409.51 K
Short % Float
2.99%
+19.35%Week
+1,158.5%1 Month
+233.39%3 Month
-66.24%6 Month
-99.93%5 Year
-99.96%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
49.14 M
EPS (TTM)
29.43
P/E Ratio
0.06
Ent. Value
49.02 M
Total Shares
11.16 M
Float Shares
2.49 M
Insiders
12.91%
Institutions
2.44%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PHGE Catalyst Timeline
Dated clinical, regulatory and corporate events for BiomX Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for BiomX Inc.
259Total events
7Upcoming
77Tier-1 (high impact)
2019 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Management ChangeCorporate
Corporate name and ticker symbol changes to Tessera Defense and Homeland Security Inc. (HLSQ) become effective
●Timing GuidancePresentation
Common stock to begin trading under symbol HLSQ on NYSE American
▲Product LaunchPost-Market
Zorronet launches no-code capability for AI-powered command-and-control platform
▲Partnership / LicenseCorporate
BiomX obtains exclusive license to develop and distribute drone testing solutions
◆AcquisitionCorporate
BiomX amends Zorronet acquisition terms, extends promissory note maturity to November 1, 2026
●Quarterly UpdateCorporate
BiomX to make initial principal payment of $250,000 on promissory note
▲Partnership / LicenseCorporate
Zorronet enters strategic collaboration with Samura s.r.o. for AI-powered monitoring solutions
●Oral PresentationPresentation
DFSL to showcase LADAR-based counter-drone solutions at ISC 2026
◆Topline ReadoutBX004Clinical Data
Topline results expected from Phase 2b trial
cystic fibrosis with chronic Pseudomonas aeruginosa pulmonary infectionsource ↗
◆Topline ReadoutBX211Clinical Data
Second readout (Week 52) for Phase 2 trial of BX211 evaluating amputation rates and resolution of osteomyelitis
diabetic foot osteomyelitis associated with Staphylococcus aureussource ↗
▼Trial DiscontinuedBX004Trial
Discontinuation of Phase 2b BX004 trial following DMC feedback and internal analysis
Cystic Fibrosis with chronic Pseudomonas aeruginosa infectionssource ↗
▼Restructuring LayoffsCorporate
Cost-cutting measures including significant workforce reduction
◆Pipeline PrioritizationBX011Corporate
Focus on BX011 development for S. aureus DFI
Staphylococcus aureus infections associated with diabetic foot infectionssource ↗
◆DSMB ReviewBX004Trial
DMC safety review for BX004 Phase 2b trial
Cystic Fibrosis with chronic Pseudomonas aeruginosa infectionssource ↗
▼Clinical Hold PlacedBX004IND
FDA clinical hold on BX004 Phase 2b trial due to nebulizer device
cystic fibrosissource ↗
●Protocol AmendmentBX004Trial
Protocol updated per DMC recommendation for adjusted dosing
cystic fibrosissource ↗
◆Restructuring LayoffsCorporate
Deadline to regain compliance with NYSE American continued listing standards
▲FDA Feedback ReceivedBX011FDA Meeting
Positive FDA feedback on clinical developmental pathway for BX011 in DFI
diabetic foot infectionssource ↗
▼Clinical Hold PlacedBX004IND
FDA clinical hold placed on U.S. portion of BX004 Phase 2b trial
cystic fibrosis with chronic Pseudomonas aeruginosa infectionsource ↗
▲FDA Feedback ReceivedBX004FDA Meeting
FDA provided written feedback on potential development pathways for BX004
cystic fibrosis with chronic Pseudomonas aeruginosa infectionsource ↗
▲FDA Feedback ReceivedBX011FDA Meeting
Positive FDA feedback confirming clear clinical development path for BX011
Staphylococcus aureus in Diabetic Foot Infectionssource ↗
▲FDA Feedback ReceivedBX004FDA Meeting
Positive FDA feedback providing guidance for potential Phase 3 development pathways for BX004
Chronic Pseudomonas aeruginosa in cystic fibrosissource ↗
●Runway Guidance UpdateCorporate
Cash runway guidance: sufficient to fund operations through Q4 2025
◆Oral PresentationPresentation
CEO Jonathan Solomon presents at H.C. Wainwright 27th Annual Global Investment Conference
▼Clinical Hold PlacedBX004IND
FDA placed clinical hold on Phase 2b trial due to third-party nebulizer device
cystic fibrosis with chronic Pseudomonas aeruginosa lung infectionssource ↗
▼Enrollment PausedBX004Trial
Patient screening and enrollment paused in U.S. portion of Phase 2b trial
cystic fibrosis with chronic Pseudomonas aeruginosa lung infectionssource ↗
▲First Patient DosedBX004Trial
Phase 2b trial of BX004 has successfully commenced patient dosing
Cystic Fibrosis with chronic Pseudomonas aeruginosa lung infectionssource ↗
▲PublicationBX004Presentation
Nature Communications publication of BX004 Phase 1b/2a data
Cystic Fibrosis with chronic Pseudomonas aeruginosa lung infectionssource ↗
▲First Patient DosedBX004Trial
First patient dosed in Phase 2b trial of BX004
cystic fibrosis with chronic Pseudomonas aeruginosa lung infectionssource ↗
▲PublicationBX004Presentation
Publication of Phase 1b/2a Part 1 data in Nature Communications
cystic fibrosis with chronic Pseudomonas aeruginosa pulmonary infectionsource ↗
◆Topline ReadoutBX004Clinical Data
Topline results from Phase 2b trial of BX004 expected in Q3 2025
cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infectionssource ↗
Past FDA Catalysts and PDUFA Decisions
How PHGE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | BX004 | Phase 2b topline data readout | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D20 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.0x
rNPV / MCap
BiomX Inc. faces pipeline headwinds (20/100), with $177M risk-adjusted pipeline value, led by BX002-A in Healthy Volunteers (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BX002-A Monoclonal antibodyCompletedNCT04737876 | Healthy Volunteers | Phase 1 | COMPLETED | 18 | Dec 21, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every PHGE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BX004 Fast TrackOrphan | cystic fibrosis | Phase 2b | 2025-11-25 | improvement in pulmonary function associated with a reduction in P. aeruginosa burden versus placebo in a predefined subgroup of patients with reduced lung function (baseline FEV1<70%)Read More | BiomX Provides Update on BX004 Phase 2b Trial in Cystic FibrosisRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Yeganeh ReuvenDirector, 10% Owner | Sell | -530,000 | $5.00 | 03/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PHGE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 6.00 K | 19.47 K |
PHGE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PHGE ranks across every disease it competes in
Competitive Position is a premium feature
See how PHGE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPHGE News
About BiomX Inc.
Headquarters850 NEW BURTON ROAD, DOVER, DE, 19904
Founded13-03-2019
BIOPHARMAWATCH ELITE PLUS
Trade the next PHGE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime